DailyIQ
Last updatedUpdating…

CYTK·Cytokinetics Incorporated

$61.12
-0.23 (-0.37%)
After Hours
High
$62.05
Open
$61.09
Market Cap
8.49B
52W High
$93.51
Low
$60.15
P. Close
$61.12
P/E
-
52W Low
$54.30
Fwd P/E
-13.84
DailyIQ Est.
$116.75
Inst. Ownership
1.8%
Short Interest
12.59%
Days to Cover
10.6
Technical Score (1D)
14
BEARISH
News Sentiment
50
MIXED
CYTK is deeply oversold on the 1D chart at 14, with a SELL signal and declining momentum reflecting persistent selling. RSI is oversold, a backdrop where stabilization attempts become more common even if the trend is still down. Sentiment at 50 is diverging from the weakness. $58.93 is the bounce-watch zone; $63.85 is the first hurdle if a relief rally develops. The distinction that matters most here is between a bounce and a bottom - oversold conditions can produce sharp relief rallies without the underlying bearish trend actually reversing. A move back above $63.85 on real volume would start to make the bottoming case; anything less should be treated as a trade within the downtrend, not a signal that it's over.
LOW TARGET
$85 +39.1%
2 analysts
MEAN TARGET
$110 +79.8%
10 analysts
HIGH TARGET
$146 +138.9%
18 analysts
PRICE RANGE
$85.00 - $146.00
SB / B / H / S / SS
6/19/3/1/1
DAILYIQ EST.
$116.75 (+91.0%)
Bought (1Y)
0 shares
$0
Sold (1Y)
305,335 shares
$22.9M
Malik Fady IbrahamEVP Research & Development
Option Exercise3,500 shares2026-10-06
Malik Fady IbrahamEVP Research & Development
Sell3,500 shares2026-10-06
Malik Fady IbrahamEVP Research & Development
Option Exercise3,500 shares2026-10-06
Blum Robert IPresident & CEO
Option Exercise7,500 shares2026-09-28
Blum Robert IPresident & CEO
Sell7,500 shares2026-09-28
40/ 100
Bearish
Overall: Bearish
✓Revenue growing year over year
✕Negative net margin
✕Negative operating cash flow
Net Margin
-891.6%
Revenue CAGR
0.5%
Current Ratio
4.53x
Debt / Equity
-0.44x
Return on Equity
119.0%

EPS

EstBeatMiss
$-1.59$-1.54$-1.50$-1.45$-1.41Q3'25Q3'26
QtrEstActual+/−
Q3'26$-1.43 - -
Q3'25$-1.57$-1.54+1.6%

Revenue

EstBeatMiss
$-4M$9M$21M$34M$46MQ3'25Q3'26
QtrEstActual+/−
Q3'26$41M - -
Q3'25 - $2M -

Market Data

CYTK Stock Snapshot

BEARISH14/100
$61.12+$0.00 (0.0%)
Market cap
8.49B
Day range
$60.15 – $62.05
News sentiment
50/100 · Neutral
Analyst target
$109.90 (+79.8%)
Consensus
Buy · 30 analysts
52-week range+12.6% off low · -34.6% from high
$54.30$93.51
Price $61.12 DailyIQ Est. $116.75

The trend on CYTK is bearish, and the indicator set is confirming it rather than diverging. At this size, a single catalyst moves the stock further than it would a larger peer.

Behaviour On Record

What CYTK's own history says about today's numbers

Realized volatility (21d)
32.8% 6th pct
Below its peak
-28.1%
vs 200-day average
-10.5%
Up days (1y)
47%

Cytokinetics Incorporated is currently running 32.8% annualised volatility over the last 21 sessions. Measured against CYTK's own 13 years of daily returns rather than a market-wide average, that is the 6th percentile — unusually subdued by its own history, against a typical reading of 53.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

CYTK is trading -28.1% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -41.6%, and the deepest was -76.8% in 2014. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits -10.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 24th percentile — a narrower gap than it typically runs. Over the past year CYTK closed higher on 47% of sessions, and it is currently 2 sessions into a falling streak.

On October specifically: over 13 years of records, CYTK finished the month higher 6 of 13 times, with a median return of -3.1% and an average of -1.8%. Its strongest month historically has been December at +9.9% on average, its weakest September at -4.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: CYTK has opened more than 2% away from the prior close in 413 of 3,224 sessions (12.8% of the time), with the largest gaps running +21.6% and -32.4%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,226 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against CYTK's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of CYTK's sector?

Cytokinetics Incorporated sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Biotechnology industry group, CYTK ranks 10th of 15 tracked industries, lagging.

Sector rank
#3 of 12
Sector state
Lagging
Sector rotation score
64
Industry rank
#10 of 15

Options Market

What is the options market pricing for CYTK?

CallsPuts

For Cytokinetics Incorporated's nearest expiry (2026-10-16, 9 days out), open interest is roughly balanced between puts and calls (put/call ratio of 0.91), with at-the-money implied volatility around 58.1%. The options market is pricing roughly a ±9.1% move by that expiry — a range of about $63.40–$76.10.

Put/call ratio (2026-10-16)
0.91
ATM implied volatility
58.1%
Total open interest
3,967
Expected move by 2026-10-16
±9.1% ($63.40–$76.10)

Analyst Rating Changes

Are analysts turning bullish or bearish on CYTK?

HC Wainwright & Co. most recently reiterated its rating on Cytokinetics Incorporated to Buy on Aug 31, 2026 with a price target of $140. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
HC Wainwright & Co. — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Aug 31, 2026HC Wainwright & Co.ReiteratedBuy$140
Aug 13, 2026BarclaysMaintainedOverweight$95 → $110
Aug 13, 2026JP MorganMaintainedOverweight$97 → $103
Aug 10, 2026Truist SecuritiesMaintainedBuy$106 → $112
Aug 7, 2026RBC CapitalMaintainedOutperform$117 → $112
Aug 7, 2026CitizensMaintainedMarket Outperform$105 → $110
Aug 7, 2026NeedhamMaintainedBuy$102 → $112
Jul 7, 2026RBC CapitalMaintainedOutperform$119 → $117
Jun 29, 2026UBSUpgradeNeutral → Buy$69 → $115
Jun 24, 2026MizuhoMaintainedOutperform$100 → $118
Jun 17, 2026NeedhamReiteratedBuy$102
May 19, 2026CitigroupInitiatedBuy$99

News Sentiment Analysis

Sentiment gathered from recent headlines

50/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Cytokinetics, Inc. (CYTK) announced that it would deliver four presentations at the Heart Failure Society of America Annual Scientific Meeting 2026 in Phoenix, Arizona. The schedule includes two late‑breaking clinical research presentations and two oral presentations focused on the global efficacy and exercise performance of its drug aficamten in non‑obstructive hypertrophic cardiomyopathy. The presentations are slated for October 12, 2026, during the HFSA plenary session. The announcement provides a timetable for the company’s upcoming scientific disclosures but does not report any new data or results. The event is a routine part of CYTK’s clinical communication strategy and is unlikely to materially alter investor expectations at this time.
What did this article say?
Cytokinetics (CYTK) announced the initiation of a real‑world study to assess Myqorzo in adults with symptomatic obstructive hypertrophic cardiomyopathy. The trial will enroll roughly 400 patients across 13 cardiology practices and HCM centers over a period of 12 to 36 months. Researchers will monitor safety, efficacy, symptom improvement, and patient‑reported outcomes, as well as hospitalizations, procedures, and healthcare costs. The study aims to determine whether Myqorzo can reduce invasive procedures and improve clinical management in routine practice.
What did this article say?
Cytokinetics, Inc. (CYTK) began the ASPEN‑HCM study on September 30, 2026, to evaluate the safety, effectiveness, and healthcare resource impact of its drug MYQORZO (aficamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy. The multicenter, prospective, observational trial will collect real‑world data from routine clinical practice across several sites. The study aims to provide additional evidence on MYQORZO’s clinical profile and potential value in managing obstructive HCM.
What did this article say?
Cytokinetics announced the initiation of the ASPEN-HCM clinical trial, which will evaluate the efficacy and safety of MYQORZO, an oral myosin inhibitor, in adults with symptomatic obstructive hypertrophic cardiomyopathy. The study aims to determine whether MYQORZO can reduce left ventricular outflow tract gradients and improve symptoms in this patient population. The trial represents a significant step toward advancing CYTK’s pipeline and could broaden the therapeutic options for a rare cardiac condition.
What did this article say?
On September 28, 2026, Cytokinetics CEO Robert I. Blum sold 7,500 shares of the company, amounting to $490,950, as disclosed in a Form 4 filing. The transaction reduced his direct holdings to 278,544 shares, while his total control remained at 282,710 shares. The sale did not trigger any regulatory concerns and was not accompanied by a change in company strategy or guidance. Investors may view the move as a normal portfolio adjustment rather than a signal of impending corporate change.
What did this article say?
Cytokinetics reported a sharp rise in MYQORZO patient starts, with 2,500 in Q1 and 3,000 in Q2, and prescriptions climbing to nearly 1,500. The company aims to capture 50% of new prescriptions by year‑end and plans to seek approval for MYQORZO in non‑obstructive hypertrophic cardiomyopathy. In addition, CYTK outlined its heart‑failure pipeline, noting Phase III omecamtiv mecarbil results expected in 2028 and Phase II ulacamten results in 2027, while prioritizing early‑stage development over late‑stage acquisitions.
What did this article say?
Cytokinetics (CYTK) has delivered an average annual return of 15.99% over the past 15 years, outperforming the market by 2.64% on an annualized basis. The company’s market capitalization stands at $9.70 billion. No new catalysts or guidance updates are disclosed, so the information reflects historical performance only.
What did this article say?
Cytokinetics announced that on September 15, 2026 it granted stock options and restricted stock units to 23 new employees, totaling 52,834 options and 35,025 RSUs. The RSUs will vest over a three‑year period with a 40/40/20 split. This move is a standard inducement package and does not signal any change in business strategy or financial outlook. The announcement is routine and unlikely to materially affect CYTK’s valuation or guidance. No immediate catalysts are implied beyond the standard equity compensation practice.
What did this article say?
Cytokinetics has opened applications for its ninth annual Communications Grant Program, targeting patient advocacy groups focused on hypertrophic cardiomyopathy and heart failure. The initiative aims to fund outreach, awareness campaigns, and community engagement efforts. The program is a routine corporate social responsibility effort with no immediate financial or strategic impact on CYTK’s operations.
What did this article say?
Cytokinetics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, sharing general updates on its pipeline and strategy. No new financial guidance, product milestones, or regulatory decisions were disclosed. The appearance serves primarily to maintain investor visibility rather than to signal a material change.

Technical Analysis

Real-time indicators across multiple timeframes

14
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
2 tracked managers · $186.99M combined position · 0 adding, 0 trimming, 2 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Citadel Advisors LLC• Hold1,966,7451.42%$167.55M2026-09-02
Sarissa Capital Management LP• Hold588,3570.42%$19.44M2025-08-14
Q2 2026 flow:1.97M sh bought ($167.55M)0 sh sold ($0)net +1.97M sh (+$167.55M)
Congressional Trading Activity
1 disclosed trades · ~$8.0K est. traded value · 1 buys, 0 sells
MemberChamberStateTypeAmountTradedFiled
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-112025-08-13